SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing significant market volatility driven by a disappointing first-quarter delivery report that missed analyst expectations, fueling intense community debate regarding the company's core automotive demand versus its long-term AI and robotics narrative. While some investors view the stock's weakness as a prime opportunity to buy the dip, others are aggressively betting against the position, citing concerns over declining sales, global competition, and the potential distraction of the anticipated SpaceX IPO.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh an upcoming earnings report against the backdrop of potential U.S. cannabis rescheduling and regulatory shifts. The community remains deeply divided, with some betting on a turnaround fueled by medical growth and policy changes, while others express frustration over leadership, dilution, and long-term performance.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services is trending due to significant insider and institutional accumulation coupled with an exceptionally low float, fueling community speculation about a potential short squeeze. Investors are closely monitoring upcoming earnings and company conference calls as potential catalysts to ignite further momentum.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is experiencing heightened trading activity fueled by speculative interest in the broader space sector, specifically anticipation surrounding a potential SpaceX IPO and the company's recent operational updates at the Midland Air & Space Port. The stock remains a major talking point among retail investors, who are actively debating the company's long-term viability versus the potential for a volatile short squeeze given its small float and high short interest.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is experiencing significant volatility and elevated trading volume as investors aggressively speculate on potential buyout scenarios and M&A activity following unconfirmed media reports. The community is actively debating the company's valuation as a standalone rare-disease franchise versus its appeal as an acquisition target, with many traders closely watching abnormal after-hours trading patterns for signals of a catalyst.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is surging as traders react to heightened geopolitical tensions in the Middle East following official comments that military operations in Iran will continue, fueling fears of sustained energy supply disruptions. The community is heavily focused on the potential for a prolonged conflict and its inflationary impact, with active debates centered on whether oil prices are entering a long-term structural uptrend or if the current market action is a temporary headline-driven squeeze.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as investors weigh aggressive geopolitical escalations in the Middle East and spiking oil prices against persistent market resilience. The community is actively debating whether current price action is a government-led stabilization effort, a classic bull trap, or a sign that the market is beginning to price in further macro instability.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as it joins the S&P 500 index, triggering mandatory buying from index funds and ETFs alongside continued speculative interest linked to AI infrastructure investments. The community is sharply divided, with bulls pointing to the company's critical role in the photonics supply chain and recent hyperscaler backing, while bears argue the valuation has reached unsustainable levels and is primed for a significant correction.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market activity driven by the company's strategic move to regain full ownership of its Fab 34 facility in Ireland, coupled with ongoing community discourse regarding its AI-driven CPU demand and competitive positioning in the semiconductor sector. Investors are actively debating the stock's turnaround narrative, balancing high-conviction long-term growth expectations against immediate macro volatility and conflicting technical signals.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a positive trial update for its prostate cancer candidate, rinzimetostat, combined with a $125 million private placement financing. While some investors are expressing disappointment over the dose optimization results, the community is heavily debating the stock's future potential, with many pointing to its clean safety profile, strong cash position, and heavy institutional backing as signs of a potential long-term recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendatio...

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...

Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Hennion & Walsh Asset Management Inc. cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 36.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,163 shares of the biopha...

Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Assenagon Asset Management S.A. purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent...

United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis.</li><li>The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis.</li><li>The company licensed global rights to six pre-clinical siRNA programs in February for up to $4.4 billion to expand its pipeline.</li></ul>Shares of Madrigal Pharmaceuticals Inc. (MDGL) closed 12% higher on Thursday on buyout speculation by pharma giant Eli Lilly and Company (LLY).The rumors originated after Madrigal featured on the Betaville <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.betaville.co.uk/betaville-intelligence/jrxmz7f0s1g9fqz992bo8ioi2lq6x3suvsc7">blog</a>, which highlights potential corporate transactions. The blog highlighted that the news is market gossip and added that it might be “total codswallop.”<h2 class="st-heading-2">Madrigal’s MASH Focus</h2>Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious, progressive liver disease marked by fat accumulation, inflammation, and cell damage.The company’s Rezdiffra drug is already approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis. The company is also evaluating the drug for the treatment of compensated MASH cirrhosis.<h2 class="st-heading-2">Madrigal’s Financials</h2>For full-year 2025, the company reported Rezdiffra net sales of $958.4 million. There were more than 36,250 patients on Rezdiffra as of the end of 2025, the company said.The company also licensed global rights to six pre-clinical siRNA programs from Suzhou Ribo Life Science Co. Ltd. &nbsp;and its subsidiary Ribocure Pharmaceuticals AB in February for up to $4.4 billion to expand its pipeline. The company is looking to undertake non-clinical studies for some of the candidates in 2026.In January, the company announced an exclusive global license agreement with Pfizer for Ervogastat in yet another attempt to expand its MASH pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MDGL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user opined that Lilly will be a great company to care for Madrigal while adding that the buyout must value the company between $800-$1000 per share.<stembedurl>https://www.stocktwits.com/sarkar20/message/648675460</stembedurl>Another proposed the idea of the company merging with Viking Therapeutics instead. Viking is developing a drug candidate called VK2809 for MASH as well.<stembedurl>https://www.stocktwits.com/vu_jade/message/648680850</stembedurl><a href="https://stocktwits.com/symbol/MDGL">MDGL stock</a> has gained 55% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-as-retail-traders-pile-into-obesity-pipeline-bets/cZ3sB3KRIlO">VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation

The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.

Equity

The rumors originated after Madrigal featured on the Betaville blog which highlights potential corporate transactions.


Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% Higher - Should You Buy?

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 11.7% - Should You Buy...

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$4.21	--	--	N/A
Q4 '25	-$1.00	-$2.57	-158.00%	MISSED
Q3 '25	-$2.29	-$5.08	-122.31%	MISSED
Q2 '25	-$3.55	-$1.90	46.54%	BEAT
Q1 '25	-$3.75	-$3.32	11.43%	BEAT

MDGL
Madrigal Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest MDGL News

MDGLMadrigal Pharmaceuticals Inc